The FDA has issued a revised draft guidance designed to allow for a more efficient approach to 505(q) petitions and allow the agency to focus more reviewer resources on scientific reviews.
The Association for Accessible Medicines is voicing strong opposition that the proposed U.S.-Mexico-Canada trade agreement will provide a windfall for brand-name drug manufacturers and raise prescription drug prices for patients.
The House of Representatives approved the Senate-passed versions of the Patient Right to Know Prices Act (S. 2554) and the Know the Lowest Price Act (S. 2553), thus clearing the legislation for President Trump’s consideration and signature.
NACDS praised The Patient Right to Know Drug Prices Act (S. 2554), which is part of the effort to empower pharmacists to help patients lower out-of-pocket drug costs.
Bob Richardson, the director of sales and customer industry development at Clorox, was awarded the GMDC's annual Lifetime Achievement Award at the associations Health Beauty Wellness conference.
The FDA has published 54 product-specific guidances, including 42 new guidances and 12 revised guidances that when finalized will show its expectations on how to develop generic drug products.
